245 related articles for article (PubMed ID: 25548153)
1. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.
Ji Y; Wrzesinski C; Yu Z; Hu J; Gautam S; Hawk NV; Telford WG; Palmer DC; Franco Z; Sukumar M; Roychoudhuri R; Clever D; Klebanoff CA; Surh CD; Waldmann TA; Restifo NP; Gattinoni L
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):476-81. PubMed ID: 25548153
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T
Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397
[TBL] [Abstract][Full Text] [Related]
3. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
Gattinoni L; Finkelstein SE; Klebanoff CA; Antony PA; Palmer DC; Spiess PJ; Hwang LN; Yu Z; Wrzesinski C; Heimann DM; Surh CD; Rosenberg SA; Restifo NP
J Exp Med; 2005 Oct; 202(7):907-12. PubMed ID: 16203864
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
Wrzesinski C; Paulos CM; Gattinoni L; Palmer DC; Kaiser A; Yu Z; Rosenberg SA; Restifo NP
J Clin Invest; 2007 Feb; 117(2):492-501. PubMed ID: 17273561
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
7. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
8. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.
Kosaka A; Ohkuri T; Ikeura M; Kohanbash G; Okada H
Biochem Biophys Res Commun; 2015 Mar; 458(3):549-554. PubMed ID: 25677619
[TBL] [Abstract][Full Text] [Related]
9. Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
Hunter MR; Prosser ME; Mahadev V; Wang X; Aguilar B; Brown CE; Forman SJ; Jensen MC
Mol Immunol; 2013 Nov; 56(1-2):1-11. PubMed ID: 23628622
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.
Renrick AN; Thounaojam MC; de Aquino MTP; Chaudhuri E; Pandhare J; Dash C; Shanker A
Front Immunol; 2021; 12():607044. PubMed ID: 33717088
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
13. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.
Dudda JC; Salaun B; Ji Y; Palmer DC; Monnot GC; Merck E; Boudousquie C; Utzschneider DT; Escobar TM; Perret R; Muljo SA; Hebeisen M; Rufer N; Zehn D; Donda A; Restifo NP; Held W; Gattinoni L; Romero P
Immunity; 2013 Apr; 38(4):742-53. PubMed ID: 23601686
[TBL] [Abstract][Full Text] [Related]
16. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
[TBL] [Abstract][Full Text] [Related]
17. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.
Palmer DC; Guittard GC; Franco Z; Crompton JG; Eil RL; Patel SJ; Ji Y; Van Panhuys N; Klebanoff CA; Sukumar M; Clever D; Chichura A; Roychoudhuri R; Varma R; Wang E; Gattinoni L; Marincola FM; Balagopalan L; Samelson LE; Restifo NP
J Exp Med; 2015 Nov; 212(12):2095-113. PubMed ID: 26527801
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
[TBL] [Abstract][Full Text] [Related]
19. The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21.
Iliopoulos D; Kavousanaki M; Ioannou M; Boumpas D; Verginis P
Eur J Immunol; 2011 Jun; 41(6):1754-63. PubMed ID: 21469086
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
